Singh Dolly, Dhummakupt Adit, Siems Lilly, Persaud Deborah
Department of Pediatrics, Johns Hopkins University School of Medicine.
J Infect Dis. 2017 Dec 1;216(suppl_9):S834-S837. doi: 10.1093/infdis/jix386.
Monitoring human immunodeficiency virus type 1 (HIV-1) drug resistance is critical for assessing ART effectiveness and treatment outcomes for HIV-1-infected individuals, including children, worldwide. Traditionally, testing for HIV-1 drug resistance has primarily been performed on plasma samples, and with commercially available, clinically validated assays that are costly and difficult to access. While plasma is the preferred sample for HIV-1 drug resistance genotyping, plasma analysis requires sophisticated laboratory equipment, personnel, space, and stringent storage conditions for maintenance of sample integrity and transport. With the limitations in feasibility and affordability of providing these ideal conditions for plasma genotyping in resource-constrained settings, the field has gained substantial experience with the dried blood spot (DBS) technique as an alternative. Moreover, DBS analysis can be used to comprehensively monitor the spread of the epidemic with applications to more-sensitive and quantitative technologies to assess HIV-1 globally.
监测人类免疫缺陷病毒1型(HIV-1)耐药性对于评估全球范围内包括儿童在内的HIV-1感染者的抗逆转录病毒治疗(ART)效果和治疗结果至关重要。传统上,HIV-1耐药性检测主要在血浆样本上进行,使用的是商业上可获得的、经过临床验证的检测方法,这些方法成本高昂且难以获得。虽然血浆是HIV-1耐药基因分型的首选样本,但血浆分析需要精密的实验室设备、人员、空间以及严格的储存条件以维持样本完整性和运输。鉴于在资源有限的环境中为血浆基因分型提供这些理想条件存在可行性和可负担性方面的限制,该领域已积累了大量使用干血斑(DBS)技术作为替代方法的经验。此外,DBS分析可用于全面监测疫情的传播,并应用于更敏感和定量的技术以在全球范围内评估HIV-1。